PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Parabilis Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$25.35+2.60 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $732.82M
- P/E (TTM)
- –
- Dividend yield
- –
Parabilis Medicines statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Parabilis Medicines | Industry median |
|---|---|---|
| Market Cap | $3.13B | $197.05M |
| Enterprise Value | $2.02B | $106.56M |
| PB Ratio | 2.99 | 2.14 |
| P/TBV Ratio | 2.99 | 2.46 |
Balance sheet
| Measure | Parabilis Medicines | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.12B | $62.42M |
| Total Debt | $6.41M | $120.13M |
| Net Cash (Debt) | $1.11B | $15.68M |
| Net Cash Per Share | $9.02 | $0.65 |
| Equity (Book Value) | $1.05B | $48.79M |
| Book Value Per Share | $8.48 | $1.36 |
| Tangible Book Value | $1.05B | $23.06M |
| Working Capital | $1.06B | $75.77M |
Financial position
| Measure | Parabilis Medicines | Industry median |
|---|---|---|
| Current Ratio | 17.91 | 3.30 |
| Quick Ratio | 17.83 | 2.39 |
| Debt / Equity | 0.01 | 0.51 |
Shares
| Measure | Parabilis Medicines | Industry median |
|---|---|---|
| Shares Outstanding | 123,533,000 | 59,128,900 |
| Float | 86,474,900 | 48,744,500 |
| Shares Held by Insiders | 30.0% | 11.8% |
| Shares Held by Institutions | 80.1% | 59.4% |
Scores
| Measure | Parabilis Medicines | Industry median |
|---|---|---|
| Altman Z-Score | 15.06 | 0.10 |
Calculated by StockData from Parabilis Medicines's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.